Abstracts Archive - Page 2458 of 2607 - ACR Meeting Abstracts

Abstract Number: 2190 • 2012 ACR/ARHP Annual Meeting
Antimalarials for Sjogren’s Syndrome Treatment in Adults, Meta-Analysis
Vibian A. Coy¹, Carlos E. Granados², Diana Gil¹, Alejandro Junca¹, Daniel Jaramillo¹, Antonio A. Iglesias-Gamarra³, Jose Felix Restrepo⁴ and Federico Rondon-Herrera⁴, ¹Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Fellow of Rheumatology Universidad Nacional de Colombia, Bogotá, Colombia, ²Departamento de Medicina, facultad de medicina, Professor -Universidad Nacional de Colombia, Bogotá, Colombia, ³Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Professor-Universidad Nacional de Colombia, Bogota, Colombia, ⁴Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Professor -Universidad Nacional de Colombia, Bogota, Colombia
Background/Purpose: Sjögren´s syndrome (SS) is a chronic inflammatory autoimmune disease that is presented with lymphocytic infiltration of exocrine glands. Its secondary secretory dysfunction may involved…
Abstract Number: 2191 • 2012 ACR/ARHP Annual Meeting
Secretagogue Use in Patients with Primary Sjogren’s Syndrome
Ghaith Noaiseh¹, Joshua Baker² and Frederick B. Vivino³, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Medicine, Penn Presbyt Med Ctr, Philadelphia, PA
Background/Purpose: Secretagogues are commonly used to treat xerostomia in primary Sjogren’s syndrome (pSS). Side effects and/or lack of efficacy sometimes result in cessation of…
Abstract Number: 2192 • 2012 ACR/ARHP Annual Meeting
Phenotypic Features of Sjögren’s Syndrome Among Patients with Low-Titer SSA/B Antibodies
Mara McAdams DeMarco¹, Mi Y. Lam², Stephen Shiboski², Lindsey A. Criswell³, Caroline Shiboski⁴ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁴Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The significance of a low titer of SSA and/or SSB antibodies (SSA/B-Ab) in individuals with clinical or other laboratory findings suggestive of Sjögren’s syndrome…
Abstract Number: 2193 • 2012 ACR/ARHP Annual Meeting
Validity of Low Titers of SSA/B Antibodies in Predicting A Key Feature of Sjögren’s Syndrome
Mara McAdams DeMarco¹, Mi Y. Lam², Stephen Shiboski², Lindsey A. Criswell³, Caroline Shiboski⁴ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁴Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The validity of low titers of SSA and/or SSB (SSA/B) antibodies (Ab) in the diagnosis of Sjögren’s syndrome (SS) has not been defined. We…
Abstract Number: 2194 • 2012 ACR/ARHP Annual Meeting
Cathepsin S Activity in Tears As a Marker of Sjögren’s Syndrome
S.E. Whitt¹, K. Renduchintala¹, S. Janga², M. Shah², J. Zhu³, K. Silka³, S. Bricel³, D. Bach³, M. Heur⁴, S. Christianakis⁵, J. Irvine⁴, D. Arkfeld⁶, W.J. Mack³, William Stohl⁷ and S.F. Hamm-Alvarez², ¹University of Southern California Keck School of Medicine -These authors contributed equally to this work, Los Angeles, CA, ²University of Southern California School of Pharmacy, Los Angeles, CA, ³University of Southern California Keck School of Medicine, Los Angeles, CA, ⁴Doheny Eye Institute, Los Angeles, CA, ⁵Med/Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁶Div of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁷Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Currently used biomarkers for Sjögren’s Syndrome (SS), such as anti-SSA/Ro or anti-SSB/La, lack sensitivity and specificity. The goal of the work presented here…
Abstract Number: 2195 • 2012 ACR/ARHP Annual Meeting
Long-Term Changes in Autoantibody Profile After Pandemic Unadjuvanted Influenza A/H1N1 Vaccine in Sjögren’s Syndrome
Sandra G. Pasoto¹, Ana C. Ribeiro¹, Vilma S.T. Viana¹, Elaine P. Leon², Cleonice Bueno¹, Mauricio Levy Neto¹, Alexander R. Precioso³, Maria do Carmo S. Timenetsky⁴ and Eloisa Bonfa¹, ¹Internal Medicine, Division of Rheumatology - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Instituto Butantan, São Paulo, Brazil, ⁴Instituto Adolfo Lutz - Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Despite WHO recommendations about the A/California/7/2009/H1N1-like virus vaccination, there are no studies evaluating its possible influence on clinical manifestations and autoantibody profile in (primary)…
Abstract Number: 2196 • 2012 ACR/ARHP Annual Meeting
Decreased Expression of TSLP in Labial Salivary Glands of Patients with pSS Is Associated with Local and Systemic Disease Parameters
M.R. Hillen¹, A. Bikker², A.a. Kruize², M. Wenting-van Wijk², F.P.J.G. Lafeber³, C.E. Hack⁴ and J.A.G. van Roon⁵, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Thymic Stromal Lymphopoietin (TSLP) is a potent immunomodulatory cytokine involved in Th2-mediated immune responses and homeostatic T-cell expansion. Reduced TSLP expression by intestinal epithelial…
Abstract Number: 2197 • 2012 ACR/ARHP Annual Meeting
Diagnostic Value of Blood B-Cell Subset Profiling and Autoimmunity Markers in Anti-SSA-Negative Sjögren’s Syndrome Patients
Divi Cornec¹, Alain Saraux², Jacques-Olivier Pers³, Sandrine Jousse-Joulin⁴, Yves Renaudineau³, Thierry Marhadour⁵ and Valerie Devauchelle-Pensec⁶, ¹Department of rheumatology, Brest Occidentale University, Brest, France, ²Department of rheumatology and unit of immunology (EA 2216), Brest Occidentale university, Brest, France, ³Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ⁴Rheumatology/Immunology, CHU de la Cavale Blanche, Brest, France, ⁵Rheumatology, CHU de la Cavale Blanche, Brest, France, ⁶Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France
Background/Purpose: Recently published ACR classification criteria for primary Sjögren’s syndrome (pSS) suggest considering antinuclear antibodies (ANA) titer and rheumatoid factor (RF) positivity in patients negative…
Abstract Number: 2198 • 2012 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Primary Sjogren’s Syndrome: Any Association with IgG4 Related Sclerosing Disease?
Adlene Jebakumar¹, Carlotta Nannini², Eunhee S. Yi³, Hiroshi Sekiguchi⁴, Jay H. Ryu⁵, Cynthia S. Crowson⁶ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology Unit, Prato Hospital, Prato, Italy, ³Anatomic Pathology, Mayo Clinic, Rochester, MN, ⁴Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁵Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, ⁶Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Various forms of interstitial lung disease (ILD) are associated with primary Sjögren’s syndrome. IgG4-related sclerosing disease (ISD) is a recently described systemic fibroinflammatory disease…
Abstract Number: 2199 • 2012 ACR/ARHP Annual Meeting
Elevated IgG4 Serum Levels Among Primary Sjogren’s Syndrome Patients: Do They Unmask Underlying IgG4-Related Disease?
Clio P. Mavragani¹, George Fragoulis², Dimitra Rontogianni³, Maria Kanariou⁴ and Haralampos M. Moutsopoulos², ¹Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ²Department of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ³Department of Pathology, Evangelismos General Hospital, Athens, Greece, ⁴Department of Immunology, "Aghia Sophia" Children's Hospital, Athens, Greece
Background/Purpose: To determine IgG4 serum levels in a cohort of patients fulfilling the classification criteria for primary Sjogren’s syndrome (pSS) and to explore whether they…
Abstract Number: 2200 • 2012 ACR/ARHP Annual Meeting
IgE Autoantibodies Against SSA and SSB in Patients with Sjögren’s Syndrome and Healthy Controls
Stamatina Danielides¹, Barbara Dema², Juan Rivera² and Gabor G. Illei³, ¹Nidcr, NIH, Bethesda, MD, ²Laboratory of Molecular Immunogenetics, NIAMS, NIH, Bethesda, MD, ³Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disorder, presenting as an autoimmune exocrinopathy. Although the pathogenesis of this disease is largely unknown, evidence indicates…
Abstract Number: 2201 • 2012 ACR/ARHP Annual Meeting
Involvement of Interleukin-33 in the Pathogenesis of Sjögren’s Syndrome
Ahmad Awada, Valérie Gangji and Muhammad S. Soyfoo, Rheumatology, Hôpital Erasme,Université Libre de Bruxelles, Brussels, Belgium
Background/Purpose: To investigate the role of IL-33/ST2 in the pathophysiology of primary Sjögren’s syndrome (pSS) Methods: Serum levels of IL-33 and sST2 was determined by…
Abstract Number: 2162 • 2012 ACR/ARHP Annual Meeting
Correlation of A Multi-Biomarker Disease Activity (VECTRA™ DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib
Kunihiro Yamaoka¹, Satoshi Kubo¹, Koshiro Sonomoto¹, Shintaro Hirata¹, Guy Cavet², Rebecca Bolce², Michael W. Rowe², David Chernoff², Nadine Defranoux², Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: A multi-biomarker disease activity (MBDA) score has been developed for evaluation of disease activity of rheumatoid arthritis (RA) to complement clinical assessment and to…
Abstract Number: 2163 • 2012 ACR/ARHP Annual Meeting
Abatacept Monotherapy Effectively Reduces the Frequency of Osteoclast Precursor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis and Inhibits Their Differentiation Into Osteoclasts
Sandra Mueller-Schmucker¹, Roland Axmann¹, Sonja Herman², Mario Zaiss¹, Manuela Le Bars³, Thomas Harrer¹ and Georg A. Schett⁴, ¹University of Erlangen-Nuremberg, Erlangen, Germany, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Bristol-Myers Squibb, Rueil Malmaison, France, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Bone resorbing osteoclasts origin from monocytes. We have recently shown that binding of abatacept (CTLA4-Ig) to CD80 and CD86 on the surface of monocytes…
Abstract Number: 2164 • 2012 ACR/ARHP Annual Meeting
Evidence for NF-Kb Intracellular Signaling Involvement Following CTLA4-Ig (Abatacept) Treatment of Human Macrophages
Renata Brizzolara¹, Paola Montagna¹, Stefano Soldano², Alberto Sulli³, Bruno Seriolo⁴, Barbara Villaggio⁵, Pierfranco Triolo⁶, Lamberto Felli⁷ and Maurizio Cutolo⁸, ¹Department of Internal Medicine, Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy, ³Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁵Research Laboratory of Nephrology, Department of Internal Medicine, University of Genova, Genova, Italy, ⁶Rheumatoid Arthritis Unit, Orthopedic Surgery Department, CTO Hospital, Turin, taly, Turin, Italy, ⁷Orthopedic Department, University of Genova, Genova, Italy, ⁸Research Laboratory and Academic Unit of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy
Background/Purpose: The transcription factor NF-kB is an intracellular signaling essential for the expression of a variety of immune-response genes, including those related to pro-inflammatory cytokines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].